Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From TeGenero AG

2016 – The Pharma Year In Review

As we enter a new year, Scrip takes a look at the five biggest themes that got the most hits from our readers over the last 12 months.

Brexit Commercial

Surviving a Scandal: How to Expect the Unexpected

By their very nature, crises are unexpected, which makes the planning and management involved all the more important when defining a company strategy in the modern age of 24-hour social media.


Doing the right thing in clinical trials

A newspaper has launched a campaign in the UK to review the way that clinical trials are carried out in adolescents. It follows the death of a 17-year-old girl with Ewing’s sarcoma who was rejected for inclusion in a clinical trial of an experimental anticancer product on the grounds that she was too young: the inclusion criteria specified a minimum age of 18 years. The case has become something of a cause célèbre, as the girl was only weeks away from her 18th birthday.


Stockwatch: The metamorphosys of German Biotech

The €70 million first close of Germany's Wellington Partners fourth fund on 19 September was widely lauded as a sign of recovery of the European venture capital market (, 19 September 2012). But a more tangible indication of value was the clinical progress announced in the same week by publicly-quoted German biotech Morphosys.

Dermatology Orthopedics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies